Showing 311-320 of 1781 results for "".
Currents: Energy-Based Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/currents-energy-based-devices/23333/Meet the CSF Faculty
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/meet-the-csf-faculty/23824/Get to know Dr. Todd SchlesingerPhysician Spotlight: Candrice R. Heath, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-candrice-r-heath-md/23766/Dermatology Needs You: Why We All Need to be Involved
https://practicaldermatology.com/topics/practice-management/dermatology-needs-you-why-we-all-need-to-be-involved/23689/Word of Mouth: Which Review Sites Carry the Most Weight?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/word-of-mouth-which-review-sites-carry-the-most-weight/20396/A State of Transition for EHRs
https://practicaldermatology.com/topics/practice-management/a-state-of-transition-for-ehrs/22953/As practitioners await the next step in the larger implementation of this technology, an emphasis on utility is more important than ever.Pearls for Choosing and Initiating Psoriasis Therapy
https://practicaldermatology.com/topics/psoriasis/PD0309_18-php/22872/Members of the psoriasis panel at the 2009 South Beach Symposium last month offered insights on patient care.DermWireTV: Derm Salaries Down, Allergan Eyes Soliton, Emsculpt Week
https://practicaldermatology.com/topics/practice-management/dermwiretv-derm-salaries-down-allergan-eyes-soliton-emsculpt-week/19941/Just under half of all physicians in the US are employed in physician-owned medical practices, new data from the American Medical Association show. Medscape’s annual Physician Compensation Report reveals that physicians overall saw a reduction in income due to the COVID-19 pandemic; income for dermDermWireTV: Sotyktu Approval, Cetaphil at 75, Psoriasis/Depression Link
https://practicaldermatology.com/topics/psoriasis/dermwiretv-sotyktu-approval-cetaphil-at-75-psoriasisdepression-link/20138/FDA has approved Bristol Myers Squibb’s Sotyktu (deucravacitinib) for the oral treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. April Armstrong, MD discusses the first TYK-2 inhibitor approved for psoriasis. As Cetaphil (Galderma)New Products and Devices
https://practicaldermatology.com/columns/new-products/new-products-and-devices/20567/New products and pharmacologic developments